Stroke and Left Ventricular Assist Device (LVAD)

Robert P. From, David Hasan, Michael T. Froehler, Jennifer L. Goerbig-Campbell

Department of Anesthesia, Roy J. and Lucille A. Carver College of Medicine, Iowa City, USA.
Email: robert-from@uiowa.edu

Received October 6th, 2012; revised November 14th, 2012; accepted December 7th, 2012

ABSTRACT

Treatment of ischemic stroke for a patient on left ventricular assist device (LVAD) by neurointerventional means is rare and many anesthesia providers are unfamiliar with both LVAD and neurointerventional protocols. Examples of this include: 1) filling for continuous-flow LVAD depend on preload and the flow is inversely related to afterload; as mean arterial pressure (MAP) increases above 80 to 90 mm Hg, flow decreases; 2) there may be no palpable pulse in patients with continuous flow LVADs; 3) pulse oximetry may not work when pump flow is high and native myocardial function is minimal; 4) increasing MAP above 80 mm Hg potentially will maintain ischemic brain tissue—the penumbra—until flow is restored. This latter example creates a paradoxical management goal: increasing the mean arterial pressure (MAP) above 80 mm Hg while maintaining ischemic brain tissue, may decrease flow to the LVAD. Finally, there is controversy regarding which type of anesthesia is most efficacious for neurointerventional procedures. We describe three patients on LVAD suffering ischemic stroke requiring anesthesia for embolectomy and angioplasty during neurointerventional radiology procedures.

Keywords: Stroke; Heart Failure; Endovascular; Embolectomy; Neurointerventional; HeartMate II®; LVAD

1. Introduction

Anesthesia providers familiar with neurointerventional protocols are often unfamiliar with patients on left ventricular assist devices (LVAD), these devices have a portable, self-contained, external pump which pushes blood from the left ventricle to the aorta while noncardiac anesthesiologists are unfamiliar with patients who require endovascular therapy for acute stroke. The limited time-critical period for endovascular therapy for stroke often requires care by anesthesia providers who are not expert in either field. General perioperative management principals of patients on LVAD have been discussed [1,2]. Specific reports for intra-abdominal, laparoscopic thoracotomy, and otologic procedures have also been described [3-6]. Care for patients with acute stroke on LVAD has not been discussed and presents a unique paradox.

Maintaining a mean arterial pressure (MAP) of at least 80 mm Hg might be considered standard of care during most neurointerventional procedures involving stenotic lesions, but higher pressures are needed if angiographic evidence of ischemia is seen. On the other hand, flow through a LVAD is inversely related to afterload, or, in other words, MAP. As MAP increases above 90 mm Hg, flow decreases [7]. The relative infrequent occurrence of ischemic stroke and treatment by neurointerventional means, competition for blood pressure control combined with unfamiliarity of many anesthesia providers with LVAD, creates management challenges for care of these patients. We describe three patients on continuous flow LVAD (HeartMate II® LVAD, Thoratec Corporation, Pleasanton, CA) who developed thrombotic stroke treated by recanalization with angioplasty and stenting or mechanical thrombectomy. We discuss the anesthetic treatment challenges and review considerations for management in this select group of patients. Our Institutional Review Board determined that this project did not meet the regulatory definition of human subjects research and did not require review. Patients or family members of patients gave written consent for their case histories to be presented.

1.1. Case 1

A 35-year-old male with non-ischemic cardiomyopathy, continuous flow LVAD, and implantable cardiac defibrillator presented with anorexia, abdominal pain, bloody stools, and INR of 9.2. A “code stroke” was initiated at 6 am, the morning following admission to the cardiovascular intensive care unit (CVICU) when marked left central facial paresis was noted. The patient had a calculated NIH Stroke Scale of 6 (0 = no stroke, 21 - 42 = severe stroke). Multidetector computed tomography with an-
igiology (CTA) showed a distal occlusion of the middle cerebral artery consistent with an embolus. After arrival at the neurointerventional suite, his LVAD was attached to a battery console. Parameters included the following: pump flow 4.6 L/min; pump speed 9200 rpm; pulse index 5.4 L/min; and pump power 5.7 watts. No peripheral pulses were palpable. Initial blood pressure was 110/72 mm Hg using a blood pressure cuff with a mean of 90 mm Hg. The surgeon emphasized the importance of keeping the patient’s blood pressure up with a MAP of at least 80 mm Hg; while the physician accompanying him from the CVICU cautioned that a MAP above 90 mm Hg would decrease LVAD flow (which, in turn, would decrease cerebral perfusion rather than increase it). Prior to induction of general anesthesia, a right radial artery arterial line was placed with ultrasonic guidance. Ketamine was used for induction and maintenance continued with isoflurane. A phenylephrine infusion was used to maintain MAP between 80 and 90 mm Hg throughout the procedure. Anesthesia start to stop time was 3 hours 17 minutes. Endovascular intervention consisted of recanalization of the right middle cerebral artery by balloon angioplasty and stenting. Occlusion was thought to be due to thromboembolization. The patient was extubated immediately following the procedure. At discharge, his neurologic symptoms had resolved.

1.2. Case 2
A 55-year-old female with non-ischemic cardiomyopathy and placement of continuous flow LVAD was admitted for colposcopy and biopsy. The procedure was completed with general endotracheal anesthesia. The next morning, the patient became acutely unresponsive, requiring urgent intubation. A basilar artery thrombus was identified, for which she underwent endovascular mechanical thrombectomy. Sedation and local anesthesia were provided by the neurointerventional service. Eleven days later, she developed right hemiparesis and aphasia due to a new left middle cerebral artery (MCA) embolism, and again underwent emergent thrombectomy. Monitored anesthesia care was provided. Seven days following this procedure, she suffered a third stroke characterized by acute left hemiparesis and unresponsiveness, requiring emergent intubation. She underwent a third thrombectomy procedure, this time for the right MCA. General anesthesia was provided. One month later, the patient was discharged to home care, was alert and oriented with dysarthria. The LVAD was connected to an external battery source during all her procedures. Blood pressure cuff was used during the first and last procedure; a radial artery catheter was placed with ultrasonic guidance for the second procedure. Anesthetic agents included etomidate (Amidate®), midazolam (Versed®), fentanyl, and isoflurane.

1.3. Case 3
A 61-year-old female with ischemic cardiomyopathy and continuous flow LVAD was admitted for pneumonia. Her hospital course was complicated by renal failure and femoral artery thrombosis and embolectomy. Five days following this procedure, she became drowsy and unresponsive. An embolus to the left MCA was identified. The patient underwent emergent clot aspiration of the left MCA. Monitoring and conscious sedation was performed by a nurse. Even though circulation was restored, her condition deteriorated with further evolution of the MCA stroke. She required intubation and blood pressure support. Her family declined further imaging studies and care was withdrawn.

2. Discussion
At our institution, 64 patients have received a HeartMate II® LVAD from May 2008 through May 2012. Nine patients developed strokes: four with ischemic stroke; one with hemorrhagic stroke; and four with embolic strokes one or more times.

Support for the failing heart includes medications and devices. Ventricular assist devices have evolved from large noisy consoles connected to patients by tubes to small implanted pumps with a driveline connected to a portable external power system. Devices can assist the right (RVAD) or left ventricle. When both ventricles are supported, the term biventricular assist device (BiVAD) is used. A RVAD pushes blood from the right ventricle to the pulmonary artery; a LVAD pushes blood from the left ventricle to the aorta [8].

The LVAD is used as a bridge for patients awaiting heart transplant or as destination therapy for patients unsuitable for transplantation. About 80% of LVAD implantations are for bridge therapy [9]. These devices can have a pumping chamber and valves which allow pulsatile flow or a rotary pump that creates continuous-flow, where no pulse is detectable unless the native heart is able to create enough cardiac output so that a pulse can be felt. For a LVAD, the inflow cannula is placed into the apex of the left ventricle and the outflow cannula is inserted into the base of the aorta above the coronary arteries. The HeartMate II® is a continuous-flow LVAD Figure 1. It is the only pump approved by the FDA for bridge and destination therapy [10]. Flow through the device is determined by the speed of the pump and the differential pressure between the left ventricle and the aorta [10]. Increasing preload or decreasing afterload will increase flow through the LVAD.

Flow through the device is inversely related to afterload. Against low resistance (i.e. low afterload or MAP) the device can generate high flow, but as afterload increases there is insufficient power to overcome the resistance [11]. A MAP between 65 to 75 mm Hg during
LVAD support has been recommended [12]. Mean arterial pressures between 70 and 90 mm Hg are typically used in clinical practice. When the HeartMate II® is connected to a Display Module, the display provides pump speed in revolutions per minute (rpm), estimated flow in L/min, power in Watts, and a pulsatility index (PI). Figure 2 A high PI may occur if the device is providing a low level of support or when the left ventricle is volume loaded; a low PI may occur when the device is providing high levels of support or the left ventricle is volume depleted. The PI typically ranges between 3 [13] and 6.

Preload, or left ventricular filling, contributes to pump efficiency. Low volume status or high pulmonary artery pressure, which decreases filling of the right ventricle, will decrease pump output. Also, since the right ventricle (RV) is not supported during LVAD support, unloading of the RV with an inotrope or pulmonary vasodilator, such as sildenafil (Revatio®), may be necessary. As the pump speed increases, the flow will be less pulsatile. Figure 3 shows a theoretical arterial wave form decrease as the speed increases from 4000 rpm to 12,000 rpm. As the arterial wave form oscillations decrease, a perceptible pulse and oximetry become more difficult to obtain. Increasing preload with volume or inotropes or decreasing afterload with vasodilatation may be needed. Echocardiography can be helpful to define the function of the right ventricle, evaluating for thrombus, and in assessment of LVAD function itself.

If a thromboembolic arterial occlusion of cerebral vessels leaves a core area of neuronal death surrounded by living but non-functioning tissue; this ischemic penumbra may be salvaged if perfusion is restored [14]. Four avenues of treatment have been proven efficacious. First, rapid “door-to-needle” intervention with intravenous tissue-type plasminogen activator (tPA) within up to 4.5 hours of stroke onset can dissolve the occlusion, although a target of ≤60 minutes is the goal [15,16]. Second, endovascular therapy within six to eight hours following symptoms onset has been demonstrated to provide positive outcomes [17-19]. Third, direct intraarterial thrombolysis with prourokinase (ProUK) (not available in the US market) or tPA combined occasionally with mechanical thrombectomy up to 6 hours following onset of stroke symptoms [17,20]. Finally, transluminal angioplasty with or without stenting [21].

Perfusion to the penumbra by raising the blood pressure is controversial. Current American Heart Association guidelines state that drug-induced hypertension is not recommended for treatment of most patients with acute ischemic stroke [22]. However, small clinical studies suggest that drug induced hypertension could be used in select patients [22]. Treatment to lower blood pressure in acute ischemic stroke is not advocated unless other major end-organ damage is present [14,22]. Hypotension during induction of anesthesia may worsen the ischemic insult [23]. A Cochrane Review found that acute stroke is associated with high blood pressure in 75% of patients [24]; but there is little evidence to guide blood pressure-management in anesthetized or sedated patients [23].

Anesthesia for the three cases described consisted of three general anesthetics, one using monitored anesthesia care provided by an anesthesia team and two with nurse sedation. Conscious sedation during endovascular therapy for acute stroke is advocated by some [23,25-27] and cautioned by others [28-31]. A summary of arguments touting one method of anesthesia over another is presented in Table 1.
To settle the argument, we speculate that a large multicenter randomized control trial similar to one provided by the GALA Trial Collaborative Group (General anaesthesia versus local anaesthesia for carotid surgery [GALA]: a multicenter randomized controlled trial) [31] will need to occur for endovascular procedures as it did for carotid surgery. The GALA trial concluded that the anesthesiologist and surgeon, in consultation with the patient, should decide which anesthetic to use on an individual basis.

3. Conclusion

Newer LVADs in combination with anticoagulation decrease the likelihood of ischemic stroke. Nevertheless, when stroke does occur, an endovascular intervention is needed; it is imperative that anesthesia care providers have an understanding of both LVAD and endovascular protocols to provide optimal care during a time-critical period.

4. Acknowledgements

The Authors wish to thank the patients and their families who graciously agreed to allow their case history to be presented in this report.

REFERENCES


doi:10.1212/WNL.0b013e31826959c2

doi:10.1016/S0140-6736(08)61699-2